USE OF DUAL AND TRIPLE INCRETIN AGONISTS (TIRZEPATIDE AND RETATRUTIDE) IN THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS
DOI:
https://doi.org/10.56238/levv17n59-045Keywords:
Obesity, Type 2 Diabetes Mellitus, Tirzepatide, Retatrutide, Incretin AgonistsAbstract
Obesity and type 2 diabetes mellitus (T2DM) represent major global public health challenges, requiring more effective and integrated therapeutic strategies. In this context, dual and triple incretin agonists have emerged as innovative approaches by targeting multiple metabolic pathways simultaneously. This study aimed to provide a critical and comparative analysis of tirzepatide and retatrutide in the treatment of obesity and T2DM, based on recent scientific evidence. This narrative critical-analytical review was conducted through a structured search in PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, and Cochrane Library, including studies published between 2016 and 2025. A total of 20 studies were included, comprising clinical trials, systematic reviews, meta-analyses, and narrative reviews. The findings indicate that tirzepatide demonstrates well-established efficacy in glycemic control and weight reduction, whereas retatrutide shows greater potential for weight loss, likely related to increased energy expenditure mediated by glucagon receptor activation. However, this apparent superiority is accompanied by a higher incidence of adverse events and limited long-term evidence. The lack of direct head-to-head clinical trials and methodological heterogeneity across studies limit definitive conclusions regarding their comparative effectiveness. Therefore, although dual and triple incretin agonists represent a significant advancement in the management of obesity and T2DM, further long-term and head-to-head comparative studies are required to define their role in clinical practice.
Downloads
References
BAILEY, C. J.; FLATT, P. R.; CONLON, J. M. Recent advances in peptide-based therapies for obesity and type 2 diabetes. Peptides, v. 173, 2024. DOI: https://doi.org/10.1016/j.peptides.2024.171149.
BAILEY, C. J.; FLATT, P. R.; CONLON, J. M. An update on peptide-based therapies for type 2 diabetes and obesity. Peptides, v. 161, 2023. DOI: https://doi.org/10.1016/j.peptides.2023.170939.
CARUSO, I. et al. Incretin-based therapies for the treatment of obesity-related diseases. npj Metabolic Health and Disease, v. 2, 2024. DOI: https://doi.org/10.1038/s44324-024-00030-5.
FERNANDEZ, C.; LAKSHMI, V.; PAPPACHAN, J. M. Efficacy and safety of incretin co-agonists: transformative advances in cardiometabolic healthcare. World Journal of Cardiology, v. 17, 2025. DOI: https://doi.org/10.4330/wjc.v17.i8.107991.
FIORUCCI, S.; URBANI, G. Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives. Expert Opinion on Investigational Drugs, v. 34, p. 655–663, 2025. DOI: https://doi.org/10.1080/13543784.2025.2546812.
GALLWITZ, B. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type 2 diabetes and obesity. Frontiers in Endocrinology, v. 13, 2022. DOI: https://doi.org/10.3389/fendo.2022.1004044.
GOGINENI, P. et al. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? Expert Opinion on Pharmacotherapy, v. 25, p. 801–818, 2024. DOI: https://doi.org/10.1080/14656566.2024.2356254.
GOLDNEY, J. et al. Triple agonism based therapies for obesity. Current Cardiovascular Risk Reports, v. 19, 2025. DOI: https://doi.org/10.1007/s12170-025-00770-z.
LEMPESIS, I. G.; LIU, J.; DALAMAGA, M. The catcher in the gut: tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity. Metabolism Open, v. 16, 2022. DOI: https://doi.org/10.1016/j.metop.2022.100220.
LIARAKOS, A. L.; KOLIAKI, C. Novel dual incretin receptor agonists in the spectrum of metabolic diseases with a focus on tirzepatide. Biomedicines, v. 11, 2023. DOI: https://doi.org/10.3390/biomedicines11071875.
MADSBAD, S.; HOLST, J. J. The promise of glucagon-like peptide-1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs, v. 34, p. 197–215, 2025. DOI: https://doi.org/10.1080/13543784.2025.2472408.
MELSON, E. et al. What is the pipeline for future medications for obesity? International Journal of Obesity, v. 49, p. 433–451, 2024. DOI: https://doi.org/10.1038/s41366-024-01473-y.
SALHAB, A. et al. Comparative efficacy and safety of tirzepatide vs retatrutide in weight loss: a network meta-analysis of clinical trials. Journal of the Endocrine Society, v. 9, 2025. DOI: https://doi.org/10.1210/jendso/bvaf149.169.
SINHA, B.; GHOSAL, S. Efficacy and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: a Bayesian network meta-analysis. Obesity, v. 33, p. 2046–2054, 2025. DOI: https://doi.org/10.1002/oby.24360.
SZTANEK, F. et al. New developments in pharmacological treatment of obesity and type 2 diabetes. Biomedicines, v. 12, 2024. DOI: https://doi.org/10.3390/biomedicines12061320.
THIRIVEEDI, M. et al. A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection. Annals of Medicine & Surgery, 2025. DOI: https://doi.org/10.1097/MS9.0000000000004055.
ULLAH, M.; TAMANNA, S. Obesity: clinical impact, pathophysiology, complications, and modern innovations in therapeutic strategies. Medicines, v. 12, 2025. DOI: https://doi.org/10.3390/medicines12030019.
WINKLER, G. et al. From GLP-1 receptor agonists to triple hormone receptor activation supplemented with glucagon receptor agonism. Orvosi Hetilap, v. 164, p. 1656–1664, 2023. DOI: https://doi.org/10.1556/650.2023.32894.
YAN, K.; YU, H.; BLAISE, B. Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care. Acta Diabetologica, v. 62, p. 1359–1370, 2025. DOI: https://doi.org/10.1007/s00592-025-02534-y.
ZAFFINA, I. et al. Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. Frontiers in Endocrinology, v. 14, 2023. DOI: https://doi.org/10.3389/fendo.2023.1095753.
